Company: RCUS
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001724521-25-000040
Chunk: 157

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 8
Chunk 157
---
25 (3)21 Net cash provided by (used in) operating activities(170)(306)438 Cash flow from investing activitiesPurchases of marketable securities(1,043)(788)(1,241)Proceeds from maturities of marketable securities929 982 694 Proceeds from sales of marketable securities36 24 143 Purchases of property and equipment(6)(24)(6)Other items, net— — (3)Net cash provided by (used in) investing activities(84)194 (413)Cash flow from financing activitiesProceeds from issuance of common stock ($228, $20 and $— from a related party), net228 25 — Proceeds from debt issuances, net47 — — Proceeds from issuance of common stock pursuant to equity award plans9 8 23 Payments of employee taxes related to net settlement of equity awards(7)— — Proceeds from sale of future royalties— — 10 Net cash provided by financing activities277 33 33 Net increase (decrease) in cash, cash equivalents and restricted cash23 (79)58 Cash, cash equivalents and restricted cash at beginning of period130 209 151 Cash, cash equivalents and restricted cash at end of period$153 $130 $209 Supplemental disclosure of cash flow informationIncome taxes paid$— $5 $3 Interest paid$1 $— $— Non-cash investing and financing activities:Unpaid portion of property and equipment purchases included in Accounts payable and Other current liabilities$— $2 $3 

See accompanying notes.

78